Eli Lilly Expands U.S. Footprint With $6B Alabama Plant To Boost Obesity Pill Output

Benzinga

Eli Lilly will invest $6B in a new Huntsville plant to scale production of its experimental obesity pill and other drugs, part of a broader U.S. manufacturing build-out driven by supply-chain and tariff concerns. Construction begins in 2026 and runs through 2032, adding thousands of jobs.

Transcript

00:00It's Benzinga, bringing Wall Street to Main Street.

00:03Eli Lilly will spend $6 billion to build a manufacturing plant in Huntsville, Alabama,

00:07to boost production of its experimental obesity pill and other medicines, according to CNBC.

00:13The company said construction will begin in 2026 and finish in 2032. The pharmaceutical

00:19giant announced in February that it will spend at least $27 billion to build four new U.S.

00:25manufacturing plants, adding to $23 billion in investments since 2020.

00:30CEO David Ricks said in a press release that the investment will expand U.S. active

00:34pharmaceutical ingredient production to improve supply chain resilience and ensure reliable

00:39patient access to medicines. Drug makers increased U.S. production after Trump threatened tariffs on

00:44imported pharmaceuticals, but those concerns eased after drug pricing deals exempted companies from

00:50the levies. Eli Lilly said the site will bring 450 jobs and 3,000 construction jobs to Huntsville.

00:56For all things money, visit Benzinga.com.

01:00.

01:01.

01:02.

01:04.

01:06.

01:07.

01:08.

01:09.

01:10.

01:10SPEAKER 분들이

Category

Transcript

Be the first to comment

Recommended